Lupin receives approval from U.S. FDA for Travoprost Ophthalmic Solution USP

Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Travoprost Ophthalmic Solution USP, 0.004% (Ionic Buffered Solution), to market a generic equivalent to the reference listed drug (RLD) Travatan Z® Ophthalmic Solution, 0.004%, of Sandoz Inc. The product will be manufactured at Lupin's Pithampur facility in India.

Travoprost Ophthalmic Solution USP, 0.004%, is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. Travoprost Ophthalmic Solution USP, 0.004% (RLD Travatan Z®), had estimated annual sales of USD 77 million in the U.S. (IQVIA MAT March 2024).

Shares of Lupin Limited was last trading in BSE at Rs. 1679.75 as compared to the previous close of Rs. 1655.25. The total number of shares traded during the day was 64725 in over 4409 trades.

The stock hit an intraday high of Rs. 1687.30 and intraday low of 1635.45. The net turnover during the day was Rs. 107682045.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 USFDA Approval ANDA TravoprostOphthalmicSolution